So much BOT effort for so little, page-58

No, I'm interested in discussion. If you have anything to add to the substantive issues, please do.

So far the substantive issues are all related to the ultimate question of risk v reward:

Is a capital raising likely? My view is not very, since we appear closer to market in Japan and the US.

Is there likelihood of patient rejection? My view is no, that patient safety has been established in stage 1 and 2.

Is there likelihood of clinical failure? My view is that this appears far less likely because of the very positive results in stages 1 and 2 and of the results in Japan which are fast tracking acceptance and to commercialisation stage.

Are there any barriers to producing commercial quantities?  There are also many interesting related issues, such as MSB's capacity for commercialisation.  A JV has already been established for commercial quantities.

Feel free to discuss any of these or related topics.

But as for personal attacks, it reflects badly on you just to want to focus on that.